Vaccine Research and Development
Contents of these materials
fostered unprecedented collaboration
accelerate vaccine development
Clinical trials for COVID-19
pandemic has accelerated
Therapeutics are typically antivirals or antibodies
broader geographical development
Vaccine platform technologies
COVID-19 vaccine candidates
COVID-19 vaccine candidates
Current timelines
COVID-19 vaccine manufacturers
important questions remaining
additional asset-by-asset coverage

To spotlight key assets in development, case studies have been developed that provide an asset-by-asset overview of development plans, timelines, and reasons for optimism.

Eileen Coveney, Managing Director
Jonathan Kfoury, Managing Director
Kevin Giffels, Senior Associate Consultant
Rosie Jiang, Global Healthcare Specialist
Jeffrey Holder, Engagement Manager

Please reach out to us if you would like to continue the discussion.

Related Insights